GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-04-11| COVID-19

COVID-19: Israeli Study Suggests South African Variant Can Escape Protection from Pfizer/BioNTech Vaccine

by Rajaneesh K. Gopinath
Share To

The B.1.351 coronavirus variant originally identified in South Africa can break through the protection conferred by Pfizer/BioNTech’s mRNA vaccine, Israeli scientists have found. A team from Tel Aviv University and the Clalit healthcare organization attempted a first-of-its-kind study to confirm whether new variants, B.1.351 and B.1.1.7 (originally identified in the UK), can bypass vaccine protection in a real-world setting.

Israel initiated mass vaccination of its citizens in mid-December 2020 and has since administered the most COVID-19 vaccine doses per capita in the world. By March 2021, around 80% of the eligible population were vaccinated with Pfizer/BioNTech’s BNT162b2.

 

High Prevalence of SA Variant in Vaccinated Individuals

The study compared almost 400 people who contracted COVID-19, 14 days or more after receiving at least one dose of BNT162b2, against the same number of unvaccinated patients. Although the number of B.1.351 cases was less than 1% in the study participants, data shows that the variant’s prevalence was eight times higher in patients who received two doses of the vaccine (5.4% vs. 0.7% in unvaccinated control).

“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.

 

Low Sample Size

Previously, several lab studies reported the poor protection offered by some vaccines against the South African variant. Although conducted with a meager sample size, this Israeli study provides the first real-world data showing that the vaccine is less effective against B.1.351.

The authors admitted that the study does not include an adequate sample size of the original SARS-CoV-2 strain and B.1.351 variants. But they attributed it to the rapid increase in B.1.1.7 cases and the low prevalence of B.1.351 cases in Isreal since January 2021. The study results published in the medRxiv preprint server are yet to be peer-reviewed. It remains to be seen if these claims could be validated with more data.

Related Article: Vir, GSK’s Antibody Therapy Effective Against COVID-19 Variants, Reduces Hospitalization and Deaths by 85%

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
LATEST
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top